Overview

A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects

Status:
Completed
Trial end date:
2017-01-03
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the efficacy and safety between a group that has been on Prograf twice daily therapy but converted to Advagraf once daily therapy and a group that maintained Prograf twice daily therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Astellas Pharma Korea, Inc.
Treatments:
Tacrolimus